Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Swiss Exchange  >  Roche Holding Ltd.    ROG   CH0012032048

News SummaryMost relevantAll newsSector news 
Latest news on ROCHE HOLDING LTD.
01:27p ROCHE : MILITARY $5.36 Million Federal Contract Awarded to Roche Diagnostics
12/05 ROCHE : Major PHARMAC funding package agreed with Roche
12/05 ROCHE : Gazyva/Gazyvaro Helped People With Previously Untreated Follicular Lymph..
12/04 GENENTECH : ’s Gazyva Helped People With Previously Untreated Follicular L..
12/02 SENSEONICSHOLDINGS,INC. (NYSEMKT : SENS) Files An 8-K Entry into a Material Defi..
12/01 CHUGAI PHARMACEUTICAL : Data on Bisphosphonates Reported by Researchers at Chuga..
12/01 ROCHE : Merck Expands Distribution Agreement with Roche - Press Release issued b..
12/01 CHUGAI PHARMACEUTICAL : Filing for Approval of 'Actemra' for Additional Indicati..
12/01 ROCHE : Presolicitation - Notice of Intent to Sole Source-Roche reagents
12/01 ROCHE : Presolicitation Notice - 66-- Notice of Intent to Sole Source-Roche reag..
11/30 ROCHE : The Promise and Challenge of Big Data for Pharma
11/30 ROCHE : Special Notice - 65-- 544-17-1-023-0034-Roche Diag - Hepatitis C-544 EME..
11/29 ROCHE : to sell U.S. plant to Patheon, saving about 200 jobs
11/29 The Bank of New York Mellon Corp Increases Position in Foundation Medicine In..
11/29 PATHEON : ADDING MULTIMEDIA Patheon to Acquire State-of-the-Art Manufacturing Si..
11/28 NANOPHASE TECHNOLOGIES CORPORATION ( : NANX) Files An 8-K Entry into a Material ..
11/28 Global Hepatitis C Drug Market - Merck & Co, Kenilworth, Roche, Basel GlaxoSm..
11/28 Actelion's ambitious independent-minded CEO will drive up takeover price
11/27 ROCHE : Road construction works
11/26 FOUNDATION MEDICINE INC. : (Fmi) Coo Sold $144,341.73 in Stock
11/26 Johnson & Johnson approaches Actelion about takeover deal
11/25DJJ&J Approaches Swiss Firm Actelion About Potential Deal
11/25DJJohnson & Johnson Approaches Swiss Firm Actelion About Potential Deal -- Upda..
11/25 French cancer specialist Innate Pharma can remain independent, for now - CEO
11/25 ROCHE : Diagnostics Operations Assigned Patent
11/23 GLOBAL NON-INVASIVE PRENATAL TESTING : Illumina, Thermo Fisher, Roche, Beckman C..
11/23 ROCHE : Provides Actionable Strategies to Improve Leadership Performance in New ..
11/22 Global Influenza Market - AstraZeneca, F. Hoffmann-La Roche, GlaxoSmithKline,..
11/22 FOUNDATION MEDICINE : "Don't Guess. Test." Campaign Aims to Increase Awareness o..
11/22 ROCHE : Provides Actionable Strategies to Improve Leadership Performance in New ..
11/18 ROCHE : Sector Two Maines - Construction work for a second tank to tank L Angira..
11/18 ROCHE : Biotech innovator continues on a fast track
11/18 Top British American Tobacco investor Woodford says backs Reynolds deal
11/18 Biotech innovator continues on a fast track
11/17 HALOZYME THERAPEUTICS : Announces Broad Clinical Collaboration Agreement To Eval..
11/17 ROCHE : Sign materials
11/17 ROCHE : Topographical services
11/15 Global Anti Obesity Drugs Market 2016- Pfizer, Merck, Roche, GlaxoSmithKline,..
11/15 ROCHE : Dan Zabrowski Joins Decheng Capital As Venture Partner
11/15 ROCHE : launches imCORE, a global network of cancer immunotherapy centers of exc..
11/14 ROCHE : Phase III GiACTA Study Shows Genentech's Actemra(R) is Superior to Stero..
11/14 ROCHE : Phase III GiACTA study shows Roche's Actemra/RoActemra is superior to st..
11/12 YESTAR INTERNATIONAL COMPNY : to buy stake in diagnostics products firm
11/12 ROCHE : Phase III GiACTA Study Shows Genentech’s Actemra® is Superior to S..
11/11 OPIANT PHARMACEUTICALS : Announces Appointment of Thomas T. Thomas to Board of D..
11/11 ROCHE : Russia's Biocad to continue sales of anti-cancer drugs in Sri Lanka desp..
11/11 ROCHE : Diagnostics Operations Assigned Patent
11/11 BRISTOL MYERS SQUIBB : Samsung Biologics veut devenir leader mondial
11/10 Foundation Medicine and Sarah Cannon Collaborate to Advance Personalized Medi..
11/10 NOVOGEN : Licenses Phase II-Ready Molecule from Genentech for Development in Gli..
11/10 FOUNDATION MEDICINE : Flatiron Health and Foundation Medicine Unveil Powerful On..
11/10 ROCHE : Prothena Reports Results from Phase 1b Study of PRX002 Demonstrating Rob..
11/09 Pharma, biotech shares soar as Trump win calms pricing talk
11/09 Pharma, biotech shares soar as Trump win calms pricing talk
11/09 ROCHE OFFICIAL : the activity of the pharma market in Romania is difficult to pl..
11/08 ROCHE : Federal Contracts Awarded by Federal Agencies in Illinois (Nov. 8)
11/08 FOUNDATION MEDICINE INC. : (FMI) is Trading Higher on Unusual Volume for Novembe..
11/08 ROCHE : $3.85 Billion Federal Contract Awarded to Genentech USA
11/08 5 Biggest Pharmaceutical Companies by Market Cap
11/07 Erythropoietin Market (EPO) with Focus on Asia – Industry Analysis with..
11/07 ROCHE : FDA approves Roche's VENTANA ALK (D5F3) CDx Assay for use on the VENTANA..
11/04 ROCHE : Federal Contracts Awarded by Federal Agencies in Washington (Nov. 4)
11/04 GLOBAL FIBROSIS DRUG MARKET 2016 : Roche, Boehringer Ingelheim- Major Key Player..
11/04 ROCHE : MILITARY $11.22 Million Federal Contract Awarded to Roche Diagnostics
11/04 ROCHE : City seeks aid to offset lost roche revenue
11/04 ROCHE : showcases new clinical data across a variety of blood diseases at Americ..
11/03 FOUNDATION MEDICINE : Adds Life Sciences Leader Michael R. Dougherty to its Boar..
11/03 CURIS : CRIS) Posts Wider Q3 Loss; Shares Higher
11/03 FOUNDATION MEDICINE : Announces 2016 Third Quarter Results and Recent Highlights
11/02 ROCHE : Master of work on the establishment of a transfer center
11/02 FOUNDATION MEDICINE : reports 3Q loss
11/02 FOUNDATION MEDICINE, INC. : Results of Operations and Financial Condition, Finan..
11/02 ROCHE : Mayor, Roche chairman lead Indianapolis site dedication
11/02 ROCHE : to present new data on medicines for autoimmune diseases and severe infl..
11/02 GENENTECH : to Present New Data on Medicines for Autoimmune Diseases and Severe ..
1  2  3  4  5  6  7  8  9  10Next
Financials ( CHF)
Sales 2016 51 094 M
EBIT 2016 17 510 M
Net income 2016 11 298 M
Debt 2016 10 921 M
Yield 2016 3,85%
P/E ratio 2016 17,01
P/E ratio 2017 15,31
EV / Sales 2016 3,96x
EV / Sales 2017 3,68x
Capitalization 191 397 M
More Financials
Duration : Period :
Roche Holding Ltd. Technical Analysis Chart | ROG | CH0012032048 | 4-Traders
Full-screen chart
Technical analysis trends ROCHE HOLDING LTD.
Short TermMid-TermLong Term
Technical analysis
Income Statement Evolution
More Financials
Mean consensus OUTPERFORM
Number of Analysts 28
Average target price 286  CHF
Spread / Average Target 29%
Consensus details
EPS Revisions
More Estimates Revisions
Severin Schwan Chief Executive Officer & Executive Director
Christoph Franz Chairman
Alan Hippe Chief Financial & Information Technology Officer
John Irving Bell Non-Executive Director
Andreas Oeri Independent Non-Executive Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
ROCHE HOLDING LTD.-19.65%189 885
JOHNSON & JOHNSON8.98%304 536
PFIZER INC.-2.14%191 699
NOVARTIS AG-20.79%180 598
MERCK & CO., INC.15.73%166 118
SANOFI-4.20%105 342
More Results